{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:15:02Z","timestamp":1788052502342,"version":"build-2784847793"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","award":["2025\/57\/B\/NZ1\/02424"],"award-info":[{"award-number":["2025\/57\/B\/NZ1\/02424"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["504079349"],"award-info":[{"award-number":["504079349"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119175","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:45:19Z","timestamp":1784533519000},"page":"119175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cyanoacrylic acid ester-substituted 2- and 7-azaindoles mediate potency, efficacy, and specificity toward the monocarboxylate transporters (MCTs) 1 and 4"],"prefix":"10.1016","volume":"318","author":[{"given":"Ganesh","family":"Latambale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopika","family":"Gopakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2048-8598","authenticated-orcid":false,"given":"Sven Marcel","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Juvale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119175_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.119175_bib2","series-title":"World Cancer Report: Cancer Research for Cancer Prevention","author":"Wild","year":"2020"},{"key":"10.1016\/j.ejmech.2026.119175_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100645","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ejmech.2026.119175_bib4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s40001-023-01370-6","article-title":"Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma","volume":"28","author":"Yan","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ejmech.2026.119175_bib5","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/mc.22707","article-title":"Monocarboxylate transporter 1 is a key player in glioma-endothelial cell crosstalk","volume":"56","author":"Miranda-Goncalves","year":"2017","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ejmech.2026.119175_bib6","doi-asserted-by":"crossref","first-page":"8930","DOI":"10.18632\/aging.205008","article-title":"A comprehensive survival and prognosis analysis of GPR55 expression in hepatocellular carcinoma","volume":"15","author":"Wang","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.ejmech.2026.119175_bib7","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1038\/s41598-022-07600-x","article-title":"Deprogramming metabolism in pancreatic cancer with a bi-functional GPR55 inhibitor and biased beta(2) adrenergic agonist","volume":"12","author":"Wnorowski","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119175_bib8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.phrs.2016.07.013","article-title":"Selective GPR55 antagonism reduces chemoresistance in cancer cells","volume":"111","author":"Singh","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119175_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40659-023-00443-4","article-title":"ABCA1 transporter promotes the motility of human melanoma cells by modulating their plasma membrane organization","volume":"56","author":"Wu","year":"2023","journal-title":"Biol. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119175_bib10","doi-asserted-by":"crossref","first-page":"e22125","DOI":"10.1002\/ddr.22125","article-title":"Medicinal polypharmacology: exploration and exploitation of the polypharmacolome in modern drug development","volume":"85","author":"Stefan","year":"2024","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2026.119175_bib11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2174\/0113892002266408231207150547","article-title":"The impacts and changes related to the cancer drug resistance mechanism","volume":"24","author":"Varshney","year":"2023","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.ejmech.2026.119175_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.03.001","article-title":"How the Warburg effect supports aggressiveness and drug resistance of cancer cells?","volume":"38","author":"Icard","year":"2018","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ejmech.2026.119175_bib13","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/ijc.30904","article-title":"GPR55 receptor antagonist decreases glycolytic activity in PANC-1 pancreatic cancer cell line and tumor xenografts","volume":"141","author":"Bernier","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119175_bib14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrc.2016.77","article-title":"Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?","volume":"16","author":"Hay","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119175_bib15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1440-1681.12581","article-title":"Molecular mechanisms for tumour resistance to chemotherapy","volume":"43","author":"Pan","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119175_bib16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s44319-025-00661-9","article-title":"Structure-guided screening identifies Tucatinib as dual inhibitor for MCT1\/2","volume":"27","author":"Xu","year":"2026","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ejmech.2026.119175_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0312492","article-title":"Optogenetic screening of MCT1 activity implicates a cluster of non-steroidal anti-inflammatory drugs (NSAIDs) as inhibitors of lactate transport","volume":"19","author":"Wegner","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119175_bib18","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.chembiol.2023.06.029","article-title":"Paralog-dependent isogenic cell assay cascade generates highly selective SLC16A3 inhibitors","volume":"30","author":"Dvorak","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119175_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113806","article-title":"Novel strategies to improve tumour therapy by targeting the proteins MCT1, MCT4 and LAT1","volume":"226","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib20","doi-asserted-by":"crossref","first-page":"11904","DOI":"10.1021\/acs.jmedchem.1c00448","article-title":"Discovery of 5-2-[5-Chloro-2-(5-ethoxyquinoline-8-sulfonamido)phenyl]ethynyl-4-methoxypyridine-2-carboxylic acid, a highly selective in vivo useable chemical probe to dissect MCT4 biology","volume":"64","author":"Heinrich","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.drudis.2021.01.003","article-title":"Recent developments of human monocarboxylate transporter (hMCT) inhibitors as anticancer agents","volume":"26","author":"Wu","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119175_bib22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cell.2020.11.043","article-title":"Structural basis of human monocarboxylate transporter 1 inhibition by anti-cancer drug candidates","volume":"184","author":"Wang","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119175_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112393","article-title":"Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: a review with structure-activity relationship insights","volume":"199","author":"Puri","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25092024","article-title":"Preclinical incorporation dosimetry of [(18)F]FACH-A novel (18)F-Labeled MCT1\/MCT4 lactate transporter inhibitor for imaging cancer metabolism with PET","volume":"25","author":"Sattler","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119175_bib25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.molmet.2019.07.006","article-title":"Monocarboxylate transporters in cancer","volume":"33","author":"Payen","year":"2020","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2026.119175_bib26","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.18632\/oncotarget.26760","article-title":"N-dialkyl cyanocinnamic acids as monocarboxylate transporter 1 and 4 inhibitors","volume":"10","author":"Jonnalagadda","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.119175_bib27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bbrc.2017.10.025","article-title":"Identification of a selective inhibitor of human monocarboxylate transporter 4","volume":"495","author":"Futagi","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.119175_bib28","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1016\/j.bmcl.2017.09.033","article-title":"Synthesis and evaluation of (11)C-labeled coumarin analog as an imaging probe for detecting monocarboxylate transporters expression","volume":"27","author":"Tateishi","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119175_bib29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ejphar.2015.05.049","article-title":"Inhibition of monocarboxylate transporter by N-cyanosulphonamide S0859","volume":"762","author":"Heidtmann","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119175_bib30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.mam.2012.05.003","article-title":"The SLC16 gene family - structure, role and regulation in health and disease","volume":"34","author":"Halestrap","year":"2013","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.ejmech.2026.119175_bib31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/dmd.106.012369","article-title":"Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo","volume":"35","author":"Wang","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2026.119175_bib32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00424-003-1067-2","article-title":"The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond","volume":"447","author":"Halestrap","year":"2004","journal-title":"Pflugers Arch"},{"issue":"Pt 3","key":"10.1016\/j.ejmech.2026.119175_bib33","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1042\/bj3410529","article-title":"Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes","volume":"341","author":"Broer","year":"1999","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2026.119175_bib34","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/acs.jmedchem.2c01612","article-title":"Indole derivatives as new structural class of potent and antiproliferative inhibitors of monocarboxylate transporter 1 (MCT1; SLC16A1)","volume":"66","author":"Puri","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib35","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1535-7163.MCT-17-1253","article-title":"Preclinical efficacy of the novel monocarboxylate transporter 1 inhibitor BAY-8002 and associated markers of resistance","volume":"17","author":"Quanz","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119175_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.130854","article-title":"Monocarboxylate transporter-1 (MCT-1) inhibitors screened from autodisplayed F(V)-antibody library","volume":"265","author":"Sung","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2026.119175_bib37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1021\/acschembio.2c00666","article-title":"Chemical biology approaches confirm MCT4 as the therapeutic target of a cellular optimized hit","volume":"18","author":"Kawatkar","year":"2023","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119175_bib38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1021\/acs.jmedchem.2c01342","article-title":"Discovery of clinical candidate AZD0095, a selective inhibitor of monocarboxylate transporter 4 (MCT4) for oncology","volume":"66","author":"Goldberg","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib39","doi-asserted-by":"crossref","first-page":"24415","DOI":"10.18632\/oncotarget.14705","article-title":"Radiosynthesis and validation of (+\/-)-[18F]-3-fluoro-2-hydroxypropionate ([18F]-FLac) as a PET tracer of lactate to monitor MCT1-dependent lactate uptake in tumors","volume":"8","author":"Van Hee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.119175_bib40","first-page":"2529","article-title":"Monocarboxylate transporter 1 is an independent prognostic factor in esophageal squamous cell carcinoma","volume":"41","author":"Chen","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2026.119175_bib41","doi-asserted-by":"crossref","first-page":"311 e315","DOI":"10.1016\/j.urolonc.2018.03.014","article-title":"Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis","volume":"36","author":"Cao","year":"2018","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119175_bib42","article-title":"Prognostic value of monocarboxylate transporter 1 overexpression in cancer: a systematic review","volume":"24","author":"Silva","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119175_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020380","article-title":"Monocarboxylate transporter 4 regulates glioblastoma motility and monocyte binding ability","volume":"12","author":"Lai","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.119175_bib44","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10585-010-9345-9","article-title":"Co-expression of CD147\/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression","volume":"27","author":"Chen","year":"2010","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.ejmech.2026.119175_bib45","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/sj.bjc.6605839","article-title":"Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression","volume":"103","author":"Hao","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119175_bib46","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12935-019-0889-8","article-title":"Monocarboxylate transporter 1 and monocarboxylate transporter 4 in cancer-endothelial co-culturing microenvironments promote proliferation, migration, and invasion of renal cancer cells","volume":"19","author":"Guo","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2026.119175_bib47","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.12659\/MSM.912272","article-title":"Monocarboxylate transporter 4 (MCT4) overexpression is correlated with poor prognosis of Osteosarcoma","volume":"25","author":"Liu","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ejmech.2026.119175_bib48","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1038\/s41401-025-01517-7","article-title":"Transport mechanism and drug discovery of human monocarboxylate transporter 1","volume":"46","author":"Shi","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2026.119175_bib49","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1016\/j.bmcl.2014.09.041","article-title":"An update on therapeutic opportunities offered by cancer glycolytic metabolism","volume":"24","author":"Granchi","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119175_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910616","article-title":"Monocarboxylate Transporter-2 expression restricts tumor growth in a murine model of lung cancer: a multi-omic analysis","volume":"22","author":"Khalyfa","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119175_bib51","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/jcmm.12481","article-title":"Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer","volume":"19","author":"Valenca","year":"2015","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119175_bib52","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/pros.22620","article-title":"Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer","volume":"73","author":"Pertega-Gomes","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.ejmech.2026.119175_bib53","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1042\/BJ20151120","article-title":"The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters","volume":"473","author":"Nancolas","year":"2016","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2026.119175_bib54","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cmet.2020.12.003","article-title":"The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure","volume":"33","author":"Cluntun","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2026.119175_bib55","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nchembio744","article-title":"Monocarboxylate transporter MCT1 is a target for immunosuppression","volume":"1","author":"Murray","year":"2005","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119175_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117234","article-title":"Functional and structural polypharmacology of indazole-based privileged ligands to tackle the undruggability of membrane transporters","volume":"287","author":"Stefan","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijpharm.2006.02.043","article-title":"Inhibitory effects of statins on human monocarboxylate transporter 4","volume":"317","author":"Kobayashi","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2026.119175_bib58","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbabio.2004.12.005","article-title":"Identification and characterisation of a new class of highly specific and potent inhibitors of the mitochondrial pyruvate carrier","volume":"1707","author":"Hildyard","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2026.119175_bib59","doi-asserted-by":"crossref","first-page":"7107","DOI":"10.1016\/j.bmc.2013.09.010","article-title":"Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells","volume":"21","author":"Draoui","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1432-2277.2012.01579.x","article-title":"Immunosuppressive properties of a series of novel inhibitors of the monocarboxylate transporter MCT-1","volume":"26","author":"Pahlman","year":"2013","journal-title":"Transpl. Int."},{"key":"10.1016\/j.ejmech.2026.119175_bib61","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1021\/jm060995h","article-title":"Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties","volume":"50","author":"Guile","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib62","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/med.70009","article-title":"Navigating solute carrier Transporters-A comprehensive review of functionalized small molecule probes for target identification and characterization","volume":"46","author":"Dilweg","year":"2026","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.119175_bib63","doi-asserted-by":"crossref","first-page":"69219","DOI":"10.18632\/oncotarget.18215","article-title":"Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity","volume":"8","author":"Curtis","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.119175_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54709-7","article-title":"Development of novel silyl cyanocinnamic acid derivatives as metabolic plasticity inhibitors for cancer treatment","volume":"9","author":"Nelson","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119175_bib65","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1021\/acsmedchemlett.5b00049","article-title":"Monocarboxylate transporter 1 inhibitors as potential anticancer agents","volume":"6","author":"Gurrapu","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119175_bib66","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","article-title":"A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer","volume":"29","author":"Halford","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119175_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1419110","article-title":"Medicinal polypharmacology-a scientific glossary of terminology and concepts","volume":"15","author":"Stefan","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119175_bib68","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.drudis.2011.10.003","article-title":"Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects","volume":"16","author":"Lotsch","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119175_bib69","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1021\/acsptsci.5c00430","article-title":"Target class repurposing across membrane transporter families provides privileged ligands to address specific and undruggable pharmacological targets","volume":"9","author":"Rafehi","year":"2026","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2026.119175_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117049","article-title":"Polypharmacology translates between species and phylogenetic distance: a functional, bioinformatic, and structural study on organic anion transporting polypeptides","volume":"239","author":"Stefan","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119175_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1561247","article-title":"The necessity for polypharmacological research - an editorial on 'Network Polypharmacology of ATP-binding Cassette (ABC) and Solute Carrier (SLC) Transporters'","volume":"16","author":"Rafehi","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119175_bib72","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ijbiomac.2022.07.062","article-title":"Physicochemistry shapes bioactivity landscape of pan-ABC transporter modulators: anchor point for innovative Alzheimer's disease therapeutics","volume":"217","author":"Namasivayam","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2026.119175_bib73","article-title":"Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters","volume":"2","author":"Pahnke","year":"2021","journal-title":"Free Neuropathol"},{"key":"10.1016\/j.ejmech.2026.119175_bib74","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1016\/j.csbj.2021.11.035","article-title":"Binding mode analysis of ABCA7 for the prediction of novel Alzheimer's disease therapeutics","volume":"19","author":"Namasivayam","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ejmech.2026.119175_bib75","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1016\/j.csbj.2021.05.018","article-title":"Scaffold fragmentation and substructure hopping reveal potential, robustness, and limits of computer-aided pattern analysis (C@PA)","volume":"19","author":"Namasivayam","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ejmech.2026.119175_bib76","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4155\/fmc.11.26","article-title":"Use of secondary structure element information in drug design: polypharmacology and conserved motifs in protein-ligand binding and protein-protein interfaces","volume":"3","author":"Koch","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400267","article-title":"Target repurposing unravels avermectins and derivatives as novel antibiotics inhibiting energy-coupling factor transporters (ECFTs)","author":"Haupenthal","year":"2024","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.ejmech.2026.119175_bib78","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41597-022-01506-z","article-title":"A curated binary pattern multitarget dataset of focused ATP-binding cassette transporter inhibitors","volume":"9","author":"Stefan","year":"2022","journal-title":"Sci. Data"},{"key":"10.1016\/j.ejmech.2026.119175_bib79","article-title":"Promiscuously bioactive compounds are prevalent in widely used commercial drug repurposing libraries","volume":"305","author":"Hu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib80","series-title":"Synthesis and Evaluation of Indole Cyanoacrylic Acids as Anticancer Agents","author":"Samuel","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119175_bib81","doi-asserted-by":"crossref","first-page":"9446","DOI":"10.1021\/jm300573d","article-title":"Discovery and pharmacological profile of new 1H-indazole-3-carboxamide and 2H-pyrrolo[3,4-c]quinoline derivatives as selective serotonin 4 receptor ligands","volume":"55","author":"Furlotti","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib82","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/bdd.2159","article-title":"Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example","volume":"39","author":"Chen","year":"2018","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejmech.2026.119175_bib83","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/jcph.1261","article-title":"Effect of OATP1B1\/1B3 inhibitor GDC-0810 on the pharmacokinetics of pravastatin and coproporphyrin I\/III in healthy female subjects","volume":"58","author":"Liu","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119175_bib84","doi-asserted-by":"crossref","first-page":"16807","DOI":"10.1021\/acs.jmedchem.4c01627","article-title":"Discovery and optimization of N-Heteroaryl indazole LRRK2 inhibitors","volume":"67","author":"Logan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133727","article-title":"Facile synthesis of new N1-alkylated 1H-indazole-3-carboxamide derivatives as potential anticancer agents: in vitro, ADMET prediction, and SAR studies","volume":"1269","author":"Puri","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2026.119175_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1034397","article-title":"Combining metformin with lactate transport inhibitors as a treatment modality for cancer - recommendation proposal","volume":"12","author":"Benjamin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119175_bib87","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.biochi.2025.03.002","article-title":"Metformin's anticancer odyssey: revealing multifaceted mechanisms across diverse neoplastic terrains- a critical review","volume":"233","author":"Pal","year":"2025","journal-title":"Biochimie"},{"key":"10.1016\/j.ejmech.2026.119175_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117717","article-title":"Anticancer mechanisms of metformin: a review of the current evidence","volume":"254","author":"Zhao","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2026.119175_bib89","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7150\/ijbs.33787","article-title":"Metformin induces cell cycle arrest, apoptosis and autophagy through ROS\/JNK signaling pathway in human osteosarcoma","volume":"16","author":"Li","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2026.119175_bib90","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2017.06.019","article-title":"Covalent inhibitors design and discovery","volume":"138","author":"De Cesco","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib91","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-014-0178-8","article-title":"Ibrutinib: first global approval","volume":"74","author":"Cameron","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119175_bib92","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","article-title":"Afatinib: first global approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119175_bib93","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nchembio.925","article-title":"Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles","volume":"8","author":"Serafimova","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119175_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117422","article-title":"Cooperativity between endogenous glutamylcysteinylglycine-based oligopeptides and drugs determines the function of the multidrug transporter ABCC1","author":"Stefan","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119175_bib95","doi-asserted-by":"crossref","first-page":"8758","DOI":"10.1021\/acs.jmedchem.7b00788","article-title":"9-Deazapurines as broad-spectrum inhibitors of the ABC transport proteins P-Glycoprotein, multidrug resistance-associated protein 1, and breast cancer resistance protein","volume":"60","author":"Stefan","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib96","series-title":"Purines and 9-deazapurines as Modulators of Multidrug Resistance-associated Protein 1 (MRP1\/ABCC1)-mediated Transport 14.11.2017","author":"Stefan","year":"2017"},{"key":"10.1016\/j.ejmech.2026.119175_bib97","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119175_bib99","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1021\/ci990307l","article-title":"Prediction of physicochemical parameters by atomic contributions","volume":"39","author":"Wildman","year":"1999","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.ejmech.2026.119175_bib100","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1021\/jm000942e","article-title":"Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties","volume":"43","author":"Ertl","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib98","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1021\/acs.jmedchem.5b01644","article-title":"Pyrrolopyrimidine derivatives as novel inhibitors of multidrug resistance-associated protein 1 (MRP1, ABCC1)","volume":"59","author":"Schmitt","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib101","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/cmdc.201600182","article-title":"A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules","volume":"11","author":"Daina","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119175_bib102","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1021\/jm0492002","article-title":"A bioavailability score","volume":"48","author":"Martin","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119175_bib103","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1021\/ci034243x","article-title":"ESOL: estimating aqueous solubility directly from molecular structure","volume":"44","author":"Delaney","year":"2004","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.ejmech.2026.119175_bib104","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2026.119175_bib105","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:19:51Z","timestamp":1788049191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":105,"alternative-id":["S0223523426006203"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119175","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyanoacrylic acid ester-substituted 2- and 7-azaindoles mediate potency, efficacy, and specificity toward the monocarboxylate transporters (MCTs) 1 and 4","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119175"}}